Moxonidine (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Moxonidine" in English language version.

refsWebsite

Global rank English rank

7nih.gov

4^th place

6doi.org

2^nd place

2semanticscholar.org

11^th place

8^th place

1gp2u.com.au

low place

1kup.at

low place

1aspetjournals.org

6,663^rd place

5,792^nd place

aspetjournals.org

jpet.aspetjournals.org

Fairbanks CA, Wilcox GL (July 1999). "Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 403–412. PMID 10381806.

doi.org

Weimann HJ, Rudolph M (1992). "Clinical Pharmacokinetics of Moxonidine". Journal of Cardiovascular Pharmacology. 20 (Suppl. 4): S37–S41. doi:10.1097/00005344-199220004-00008.
He MM, Abraham TL, Lindsay TJ, Schaefer HC, Pouliquen IJ, Payne C, et al. (March 2003). "Metabolism and disposition of the antihypertensive agent moxonidine in humans". Drug Metabolism and Disposition. 31 (3): 334–342. doi:10.1124/dmd.31.3.334. PMID 12584161.
Fenton C, Keating GM, Lyseng-Williamson KA (2006). "Moxonidine: a review of its use in essential hypertension". Drugs. 66 (4): 477–496. doi:10.2165/00003495-200666040-00006. PMID 16597164. S2CID 195691757.
Bamberger CM, Mönig H, Mill G, Gödde E, Schulte HM (1995). "Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH". Experimental and Clinical Endocrinology & Diabetes. 103 (3): 205–208. doi:10.1055/s-0029-1211351. PMID 7584524.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. (October 2003). "Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)". European Journal of Heart Failure. 5 (5): 659–667. doi:10.1016/S1388-9842(03)00163-6. PMID 14607206. S2CID 45883678.
Frei M, Küster L, Gardosch von Krosigk PP, Koch HF, Küppers H (1994). "Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect". Journal of Cardiovascular Pharmacology. 24 (Suppl 1): S25–S28. doi:10.1097/00005344-199424001-00005. PMID 7533223.

gp2u.com.au

"Physiotens Tablets (moxonidine) Product Information" (PDF). Abbott Australasia Pty Ltd, 32-34 Lord Street, Botany NSW 2019, Australia. Retrieved 1 September 2016.

kup.at

Farsang, C (2001). "Moxonidine: Clinical Profile" (PDF). Journal of Clinical and Basic Cardiology. An Independent International Scientific Journal. 4 (3): 197–299. Retrieved 1 September 2016.

nih.gov

pubmed.ncbi.nlm.nih.gov

He MM, Abraham TL, Lindsay TJ, Schaefer HC, Pouliquen IJ, Payne C, et al. (March 2003). "Metabolism and disposition of the antihypertensive agent moxonidine in humans". Drug Metabolism and Disposition. 31 (3): 334–342. doi:10.1124/dmd.31.3.334. PMID 12584161.
Fenton C, Keating GM, Lyseng-Williamson KA (2006). "Moxonidine: a review of its use in essential hypertension". Drugs. 66 (4): 477–496. doi:10.2165/00003495-200666040-00006. PMID 16597164. S2CID 195691757.
Fairbanks CA, Wilcox GL (July 1999). "Moxonidine, a selective alpha2-adrenergic and imidazoline receptor agonist, produces spinal antinociception in mice". The Journal of Pharmacology and Experimental Therapeutics. 290 (1): 403–412. PMID 10381806.
Bamberger CM, Mönig H, Mill G, Gödde E, Schulte HM (1995). "Growth hormone secretion in response to the new centrally acting antihypertensive agent moxonidine in normal human subjects: comparison to clonidine and GHRH". Experimental and Clinical Endocrinology & Diabetes. 103 (3): 205–208. doi:10.1055/s-0029-1211351. PMID 7584524.
Prichard BN, Owens CW, Graham BR (August 1997). "Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent". Journal of Human Hypertension. 11 (Suppl 1): S29–S45. PMID 9321737.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. (October 2003). "Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)". European Journal of Heart Failure. 5 (5): 659–667. doi:10.1016/S1388-9842(03)00163-6. PMID 14607206. S2CID 45883678.
Frei M, Küster L, Gardosch von Krosigk PP, Koch HF, Küppers H (1994). "Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect". Journal of Cardiovascular Pharmacology. 24 (Suppl 1): S25–S28. doi:10.1097/00005344-199424001-00005. PMID 7533223.

semanticscholar.org

api.semanticscholar.org

Fenton C, Keating GM, Lyseng-Williamson KA (2006). "Moxonidine: a review of its use in essential hypertension". Drugs. 66 (4): 477–496. doi:10.2165/00003495-200666040-00006. PMID 16597164. S2CID 195691757.
Cohn JN, Pfeffer MA, Rouleau J, Sharpe N, Swedberg K, Straub M, et al. (October 2003). "Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)". European Journal of Heart Failure. 5 (5): 659–667. doi:10.1016/S1388-9842(03)00163-6. PMID 14607206. S2CID 45883678.